Kura Oncology Inc

NASDAQ KURA

Data sourced from

and

Download Data

Kura Oncology Inc Depreciation and Amortization for the quarter ending March 31, 2024: USD 234.00 K

Kura Oncology Inc Depreciation and Amortization is USD 234.00 K for the quarter ending March 31, 2024, a 13.59% change year over year. Depreciation and Amortization involve the systematic allocation of the cost of tangible and intangible assets over their useful lives.

Kura Oncology Inc Depreciation and Amortization for the quarter ending March 31, 2023 was USD 206.00 K, a 16.38% change year over year.
Kura Oncology Inc Depreciation and Amortization for the quarter ending March 31, 2022 was USD 177.00 K, a 63.89% change year over year.
Kura Oncology Inc Depreciation and Amortization for the quarter ending March 31, 2021 was USD 108.00 K, a 198.18% change year over year.
Kura Oncology Inc Depreciation and Amortization for the quarter ending March 31, 2020 was USD -110.00 K, a 79.63% change year over year.

NASDAQ: KURA

Kura Oncology Inc

CEO	Dr. Troy Edward Wilson J.D., Ph.D.
IPO Date	Sept. 22, 2015
Location	United States
Headquarters	12730 High Bluff Drive, San Diego, CA, United States, 92130
Employees	142
Sector	Healthcare
Industry	Biotechnology

Description

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

Key trends